Clinical Trial Update: CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating CPI-613 (devimistat) in combination with modified FOLFIRINOX for locally advanced pancreatic ductal adenocarcinoma has been withdrawn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CPI-613 (devimistat)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: WITHDRAWN